NERVIANO, IT and BOSTON, Mass, June 21 , 2024 – Nerviano Medical Sciences S.r.l. (“NMS” or the “Company”), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announces the strategic discontinuation of three development programs to further prioritize and reinforce efforts on core programs.
- NMS-088, a next-generation, clinical-stage FLT3 inhibitor. The decision is the result of internal analysis of the benefit profile of the drug in the third line (3L) setting in patients who are refractory or relapsed after standard of care including prior FLT3 inhibitors and considering the further development in rapidly changing AML treatments. NMS will report the data in in the first half of 2025;
- NMS-173, a potent covalent orally available, second-generation dual IDH1/ IDH2 inhibitor, inducing abrogation of 2-HG production and anti-tumor efficacy in IDH mutant mouse models superior to competitors, thus suggesting potential for better efficacy in patients compared to available drugs. NMS-173 has received authorization to start phase I studies in US and Europe for the treatment of patients with IDH1 and IDH2 mutated solid tumors, including cholangiocarcinoma;
- NMS-341, a late preclinical-stage next-generation inhibitor of CDC7, with potential for Best-in- Class, due to its unique combination of potency on target, cross-reactivity to CDK9 and oral bioavailability. Based on its broad efficacy as single agent and in combination, and in view of CDC7 role in DNA-damage response, NMS-341 can be used to treat patients with a wide range of solid and hematological tumors, also in combination with chemotherapy and as radio-ligand sensitizer.
NMS is open for potential collaborations or partnerships around these assets, with the right partners to maximize the value of these trusted programs.
NMS remains committed to discover and develop innovative therapies able to address unmet medical needs in oncological patients and will continue to invest to strengthen a focused, high-impact portfolio.
PR Link: 20240621-NMS-Portfolio shaping
